Lazard Asset Management
LAB icon

Lazard Asset Management’s Standard BioTools LAB Stock Holding History

Lazard Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-282,275
Closed -$2.26M – 1020
2016
Q3 		$2.26M Sell
282,275
-35,900
-11% -$330K ﹤0.01% 613
2016
Q2 		$2.87M Sell
318,175
-71,800
-18% -$675K 0.01% 581
2016
Q1 		$3.15M Sell
389,975
-251
-0.1% -$1.81K 0.01% 554
2015
Q4 		$4.22M Sell
390,226
-149,904
-28% -$1.47M 0.01% 540
2015
Q3 		$4.38M Buy
540,130
+112,246
+26% +$1.77M 0.01% 505
2015
Q2 		$10.4M Buy
427,884
+113,024
+36% +$3.57M 0.02% 379
2015
Q1 		$13.3M Buy
314,860
+55,860
+22% +$2.21M 0.03% 316
2014
Q4 		$8.73M Buy
+259,000
New +$7.33M 0.02% 429

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lazard Asset Management's LAB Position: Q4 2016 in Review

Lazard Asset Management sold out of Standard BioTools (LAB) in Q4 2016, closing a stake of 282,275 shares — an estimated $2.26M sold.

Lazard Asset Management first reported a position in LAB in Q4 2014 and held it in 8 quarters. The position peaked at $13.3M in Q1 2015. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

  • Lazard Asset Management reported no remaining Standard BioTools position as of Q4 2016 after selling out during the quarter.
  • Lazard Asset Management sold 282,275 Standard BioTools shares in Q4 2016, an estimated $2.26M.
  • Lazard Asset Management first reported a position in Standard BioTools in Q4 2014 and held it in 8 quarters.
  • Lazard Asset Management's Standard BioTools position peaked at $13.3M in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on Lazard Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.